Stock PPGN POLYPEPTIDE GROUP AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PolyPeptide Group AG

Equities

PPGN

CH1110760852

Real-time Estimate Cboe Europe
Other stock markets
 05:10:07 2024-05-29 am EDT 		5-day change 1st Jan Change
32.58 CHF -0.08% Intraday chart for PolyPeptide Group AG -0.46% +86.64%
Mar. 12 PolyPeptide Group AG Provides Earnings Guidance for 2024 CI
Mar. 12 Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • The company has insufficient levels of profitability.
  • With an enterprise value anticipated at 3.29 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
POLYPEPTIDE GROUP AG Stock PolyPeptide Group AG
+86.64% 1.18B
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.15% 238B
B+
NOVARTIS AG Stock Novartis AG
+7.12% 204B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.42% 203B
A+
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
C+
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PPGN Stock
  4. Ratings PolyPeptide Group AG